{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["40(10)"],"submitter":["Di Meglio A"],"pubmed_abstract":["Purpose
Fatigue is common and troublesome among breast cancer survivors; however, limited tools exist to predict its risk.Patients and methods
Participants with stage I-III breast cancer were prospectively included from CANTO (ClinicalTrials.gov identifier: NCT01993498), collecting longitudinal data at diagnosis (before the initiation of any cancer treatment) and 1 (T1), 2 (T2), and 4 (T3) years after diagnosis. The main outcome was severe global fatigue at T2 (score ≥ 40/100, European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-C30). Analyses at T3 were exploratory. Secondary outcomes included physical, emotional, and cognitive fatigue (EORTC Quality of Life Questionnaire-FA12). Multivariable logistic regression models retained a"],"journal":["Journal of clinical oncology : official journal of the American Society of Clinical Oncology"],"pagination":["1111-1123"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8966972"],"repository":["biostudies-literature"],"pubmed_title":["Development and Validation of a Predictive Model of Severe Fatigue After Breast Cancer Diagnosis: Toward a Personalized Framework in Survivorship Care."],"pmcid":["PMC8966972"],"pubmed_authors":["Presti D","Michiels S","Levy C","Soldato D","Havas J","Martin AL","Everhard S","Pistilli B","Ganz PA","Charles C","Rigal O","Vaz-Luis I","Tarpin C","Andre F","Menvielle G","Martin E","Dumas A","Vanlemmens L","Partridge AH","Di Meglio A","Lin NU","Coutant C","Delaloge S"],"additional_accession":[]},"is_claimable":false,"name":"Development and Validation of a Predictive Model of Severe Fatigue After Breast Cancer Diagnosis: Toward a Personalized Framework in Survivorship Care.","description":"Purpose
Fatigue is common and troublesome among breast cancer survivors; however, limited tools exist to predict its risk.Patients and methods
Participants with stage I-III breast cancer were prospectively included from CANTO (ClinicalTrials.gov identifier: NCT01993498), collecting longitudinal data at diagnosis (before the initiation of any cancer treatment) and 1 (T1), 2 (T2), and 4 (T3) years after diagnosis. The main outcome was severe global fatigue at T2 (score ≥ 40/100, European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-C30). Analyses at T3 were exploratory. Secondary outcomes included physical, emotional, and cognitive fatigue (EORTC Quality of Life Questionnaire-FA12). Multivariable logistic regression models retained a","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Apr","modification":"2025-04-26T13:17:50.431Z","creation":"2024-11-20T21:02:26.902Z"},"accession":"S-EPMC8966972","cross_references":{"pubmed":["35061509"],"doi":["10.1200/JCO.21.01252"]}}